Investors Buy Large Volume of Roivant Sciences Put Options (NASDAQ:ROIV)

Roivant Sciences Ltd. (NASDAQ:ROIV) was the target of unusually large options trading activity on Wednesday. Stock investors purchased 2,086 put options on the stock. This is an increase of 83% compared to the typical daily volume of 1,137 put options.

Analyst Ratings Changes

ROIV has been the subject of several research reports. TD Cowen reissued a “buy” rating on shares of Roivant Sciences in a research report on Wednesday, March 4th. Piper Sandler lifted their price objective on shares of Roivant Sciences from $22.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, April 16th. Weiss Ratings restated a “sell (d)” rating on shares of Roivant Sciences in a report on Friday, May 8th. Guggenheim lifted their price target on Roivant Sciences from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Finally, Sanford C. Bernstein started coverage on Roivant Sciences in a report on Friday, March 20th. They set an “outperform” rating and a $35.00 price objective for the company. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $30.55.

Roivant Sciences Trading Up 13.4%

Shares of ROIV traded up $3.79 on Wednesday, reaching $32.00. 4,650,212 shares of the company’s stock traded hands, compared to its average volume of 5,942,261. The stock’s 50 day simple moving average is $28.38 and its two-hundred day simple moving average is $24.85. The stock has a market cap of $22.90 billion, a PE ratio of -27.29 and a beta of 1.14. Roivant Sciences has a 52-week low of $10.59 and a 52-week high of $32.53.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings data on Thursday, May 21st. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.54. Roivant Sciences had a negative return on equity of 19.04% and a negative net margin of 6,079.94%.During the same period in the prior year, the firm posted ($0.29) earnings per share. Analysts forecast that Roivant Sciences will post -1.55 earnings per share for the current year.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, insider Frank Torti sold 1,400,000 shares of the firm’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $27.42, for a total value of $38,388,000.00. Following the completion of the sale, the insider directly owned 13,736,547 shares in the company, valued at approximately $376,656,118.74. This trade represents a 9.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Eric Venker sold 200,000 shares of the company’s stock in a transaction dated Monday, April 20th. The shares were sold at an average price of $29.59, for a total transaction of $5,918,000.00. Following the transaction, the chief executive officer owned 1,647,546 shares in the company, valued at $48,750,886.14. This represents a 10.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 3,745,173 shares of company stock valued at $103,639,917 over the last 90 days. Insiders own 10.80% of the company’s stock.

Institutional Trading of Roivant Sciences

Hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE boosted its stake in Roivant Sciences by 8.0% in the first quarter. Bank of America Corp DE now owns 3,163,821 shares of the company’s stock valued at $87,638,000 after acquiring an additional 235,493 shares during the last quarter. Edgestream Partners L.P. bought a new position in shares of Roivant Sciences during the 1st quarter valued at approximately $1,130,000. Janus Henderson Group PLC increased its stake in shares of Roivant Sciences by 6.1% during the 1st quarter. Janus Henderson Group PLC now owns 3,095,448 shares of the company’s stock worth $85,790,000 after purchasing an additional 177,339 shares during the last quarter. Arkadios Wealth Advisors bought a new stake in shares of Roivant Sciences in the 1st quarter worth approximately $242,000. Finally, Amundi raised its holdings in shares of Roivant Sciences by 41.9% in the 1st quarter. Amundi now owns 1,480,970 shares of the company’s stock worth $41,023,000 after purchasing an additional 437,506 shares during the period. Institutional investors own 64.76% of the company’s stock.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.